Traynor Capital Management, Inc. Aim Immuno Tech Inc. Transaction History
Traynor Capital Management, Inc.
- $1.6 Billion
- Q3 2024
A detailed history of Traynor Capital Management, Inc. transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Traynor Capital Management, Inc. holds 11,777 shares of AIM stock, worth $2,590. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,777
Previous 11,777
-0.0%
Holding current value
$2,590
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding AIM
# of Institutions
36Shares Held
8.97MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.33MShares$952,6000.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$437,5140.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$153,6180.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$102,0830.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il458KShares$100,7080.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $10.6M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...